Choice over chance? A case study of pre-implantation genetic testing for polygenic traits

拟议的项目将探讨与胚胎植入前基因检测/诊断的商业应用相关的社会和伦理问题，多基因风险评分（prs）侧重于“复杂”的多基因特征，如精神分裂症、癌症或心血管疾病。它将以一家名为Genomic Prediction（现在的LifeView）的美国公司为重点，研究英国可能提供这种检测的监管环境，记录遗传学专业人士、生物伦理学家和生物医学研究人员的观点。所选择的方法方法——访谈和文献分析——适合探索这些问题，而且这个主题都是原创的——关于多基因风险评分的社会科学工作很少——而且在借鉴和发展文献方面，与以前的学术研究有很好的关系。围绕伦理和安全的问题是有限的，因为重点是专业人员（而不是患者/用户），并将通过标准的培训和研究伦理审查进行管理。

The proposed project will explore social and ethical issues related to the commercial application of Preimplantation genetic testing/diagnosis using Polygenic Risk Scores (PRSs) focusing on 'complex' polygenic traits such as schizophrenia, cancers, or cardiovascular diseases. Focusing on a US-based company called Genomic Prediction (now LifeView), it will examine the regulatory environment in which this testing may be offered in the UK, documenting the views of genetics professions, bioethicists and biomedical researchers. The methodological approach chosen - interviews and documentary analysis - is appropriate to explore these issues and this topic is both original - there is little social science work on polygenic risk scores - and well-placed with regard to previous scholarship in terms of drawing on and developing the literature.Issues around ethics and safety are limited since the focus is on professionals (rather than patients/users) and will be managed using standard training and research ethics review.